Intravenous immunoglobulin for preventing infection in preterm and/or low birth weight infants.
Cross Infection
/ prevention & control
Humans
IgG Deficiency
/ drug therapy
Immunoglobulin G
/ administration & dosage
Immunoglobulins, Intravenous
/ therapeutic use
Infant
Infant, Low Birth Weight
/ immunology
Infant, Newborn
Infant, Premature
/ immunology
Infant, Premature, Diseases
/ prevention & control
Randomized Controlled Trials as Topic
Journal
The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747
Informations de publication
Date de publication:
29 01 2020
29 01 2020
Historique:
entrez:
30
1
2020
pubmed:
30
1
2020
medline:
23
5
2020
Statut:
epublish
Résumé
Nosocomial infections continue to be a significant cause of morbidity and mortality among preterm and/or low birth weight (LBW) infants. Preterm infants are deficient in immunoglobulin G (IgG); therefore, administration of intravenous immunoglobulin (IVIG) may have the potential of preventing or altering the course of nosocomial infections. To use systematic review/meta-analytical techniques to determine whether IVIG administration (compared with placebo or no intervention) to preterm (< 37 weeks' postmenstrual age (PMA) at birth) or LBW (< 2500 g birth weight) infants or both is effective/safe in preventing nosocomial infection. For this update, MEDLINE, EMBASE, CINAHL, The Cochrane Library, Controlled Trials, ClinicalTrials.gov and PAS Abstracts2view were searched in May 2013. We selected randomised controlled trials (RCTs) in which a group of participants to whom IVIG was given was compared with a control group that received a placebo or no intervention for preterm (< 37 weeks' gestational age) and/or LBW (< 2500 g) infants. Studies that were primarily designed to assess the effect of IVIG on humoral immune markers were excluded, as were studies in which the follow-up period was one week or less. Data collection and analysis was performed in accordance with the methods of the Cochrane Neonatal Review Group. Nineteen studies enrolling approximately 5000 preterm and/or LBW infants met inclusion criteria. No new trials were identified in May 2013. When all studies were combined, a significant reduction in sepsis was noted (typical risk ratio (RR) 0.85, 95% confidence interval (CI) 0.74 to 0.98; typical risk difference (RD) -0.03, 95% CI 0.00 to -0.05; number needed to treat for an additional beneficial outcome (NNTB) 33, 95% CI 20 to infinity), and moderate between-study heterogeneity was reported (I IVIG administration results in a 3% reduction in sepsis and a 4% reduction in one or more episodes of any serious infection but is not associated with reductions in other clinically important outcomes, including mortality. Prophylactic use of IVIG is not associated with any short-term serious side effects. The decision to use prophylactic IVIG will depend on the costs and the values assigned to the clinical outcomes. There is no justification for conducting additional RCTs to test the efficacy of previously studied IVIG preparations in reducing nosocomial infections in preterm and/or LBW infants.
Sections du résumé
BACKGROUND
Nosocomial infections continue to be a significant cause of morbidity and mortality among preterm and/or low birth weight (LBW) infants. Preterm infants are deficient in immunoglobulin G (IgG); therefore, administration of intravenous immunoglobulin (IVIG) may have the potential of preventing or altering the course of nosocomial infections.
OBJECTIVES
To use systematic review/meta-analytical techniques to determine whether IVIG administration (compared with placebo or no intervention) to preterm (< 37 weeks' postmenstrual age (PMA) at birth) or LBW (< 2500 g birth weight) infants or both is effective/safe in preventing nosocomial infection.
SEARCH METHODS
For this update, MEDLINE, EMBASE, CINAHL, The Cochrane Library, Controlled Trials, ClinicalTrials.gov and PAS Abstracts2view were searched in May 2013.
SELECTION CRITERIA
We selected randomised controlled trials (RCTs) in which a group of participants to whom IVIG was given was compared with a control group that received a placebo or no intervention for preterm (< 37 weeks' gestational age) and/or LBW (< 2500 g) infants. Studies that were primarily designed to assess the effect of IVIG on humoral immune markers were excluded, as were studies in which the follow-up period was one week or less.
DATA COLLECTION AND ANALYSIS
Data collection and analysis was performed in accordance with the methods of the Cochrane Neonatal Review Group.
MAIN RESULTS
Nineteen studies enrolling approximately 5000 preterm and/or LBW infants met inclusion criteria. No new trials were identified in May 2013. When all studies were combined, a significant reduction in sepsis was noted (typical risk ratio (RR) 0.85, 95% confidence interval (CI) 0.74 to 0.98; typical risk difference (RD) -0.03, 95% CI 0.00 to -0.05; number needed to treat for an additional beneficial outcome (NNTB) 33, 95% CI 20 to infinity), and moderate between-study heterogeneity was reported (I
AUTHORS' CONCLUSIONS
IVIG administration results in a 3% reduction in sepsis and a 4% reduction in one or more episodes of any serious infection but is not associated with reductions in other clinically important outcomes, including mortality. Prophylactic use of IVIG is not associated with any short-term serious side effects. The decision to use prophylactic IVIG will depend on the costs and the values assigned to the clinical outcomes. There is no justification for conducting additional RCTs to test the efficacy of previously studied IVIG preparations in reducing nosocomial infections in preterm and/or LBW infants.
Identifiants
pubmed: 31995650
doi: 10.1002/14651858.CD000361.pub4
pmc: PMC6988992
doi:
Substances chimiques
Immunoglobulin G
0
Immunoglobulins, Intravenous
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
CD000361Commentaires et corrections
Type : UpdateOf
Informations de copyright
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Références
Pediatr Infect Dis J. 1993 Jul;12(7):549-58; quiz 559
pubmed: 8345995
Vox Sang. 1990;59(1):6-11
pubmed: 2204192
Scand J Infect Dis Suppl. 1990;73:17-21
pubmed: 2128662
Lancet. 1967 Apr 8;1(7493):757-9
pubmed: 4164125
Paediatr Indones. 1989 May-Jun;29(5-6):91-6
pubmed: 2510115
Clin Perinatol. 1988 Dec;15(4):755-71
pubmed: 3061698
Pediatr Clin North Am. 1988 Jun;35(3):517-33
pubmed: 3131724
Am J Dis Child. 1991 Nov;145(11):1229-30
pubmed: 1951211
Arch Dis Child. 1988 Apr;63(4):441-3
pubmed: 3284483
Pediatrics. 1997 Feb;99(2):E2
pubmed: 9099759
Changgeng Yi Xue Za Zhi. 1998 Dec;21(4):371-6
pubmed: 10074720
Am J Dis Child. 1991 Nov;145(11):1233-8
pubmed: 1951212
Pediatrics. 1966 May;37(5):715-27
pubmed: 4956666
Clin Perinatol. 1991 Jun;18(2):303-24
pubmed: 1879110
Rev Infect Dis. 1990 May-Jun;12 Suppl 4:S349-42
pubmed: 2114033
J Pediatr. 2000 Nov;137(5):623-8
pubmed: 11060526
Clin Rev Allergy. 1992 Spring-Summer;10(1-2):13-28
pubmed: 1606520
Pediatrics. 1992 Apr;89(4 Pt 2):806-7
pubmed: 1557295
S Afr Med J. 1996 May;86(5):542-5
pubmed: 8711553
J Pediatr. 1983 Aug;103(2):273-7
pubmed: 6875724
J Clin Immunol. 1990 Nov;10(6 Suppl):47S-52S; discussion 52S-55S
pubmed: 2081789
J Pediatr. 1989 Jan;114(1):168-9
pubmed: 2491888
Biol Neonate. 1993;64(2-3):110-5
pubmed: 8260542
Cochrane Database Syst Rev. 2001;(2):CD000361
pubmed: 11405962
Pediatr Infect Dis. 1986 May-Jun;5(3 Suppl):S217-9
pubmed: 3714526
Pediatr Res. 1986 Feb;20(2):175-8
pubmed: 3511443
Rev Infect Dis. 1990 May-Jun;12 Suppl 4:S392-3
pubmed: 2194265
Anesteziol Reanimatol. 2004 May-Jun;(3):41-3
pubmed: 15314858
Pediatr Infect Dis J. 1994 Dec;13(12):1122-5
pubmed: 7892082
N Engl J Med. 1994 Apr 21;330(16):1107-13
pubmed: 8133853
J Pediatr. 1991 Apr;118(4 Pt 1):557-9
pubmed: 1901082
J Pediatr. 1987 Mar;110(3):437-42
pubmed: 3102711
Indian J Pediatr. 1996 Jul-Aug;63(4):517-21
pubmed: 10832472
Cochrane Database Syst Rev. 2000;(2):CD000361
pubmed: 10796199
J Med Assoc Thai. 1991 Jan;74(1):14-8
pubmed: 1902866
Rev Infect Dis. 1990 May-Jun;12 Suppl 4:S463-8; discussion S468-9
pubmed: 2114036
Semin Perinatol. 1997 Feb;21(1):28-38
pubmed: 9190031
Pediatrics. 1991 Sep;88(3):437-43
pubmed: 1881720
Rev Prat. 1991 May 21;41(15):1368-70
pubmed: 2063136
Am J Pediatr Hematol Oncol. 1990 Winter;12(4):505-9
pubmed: 1704687
N Engl J Med. 1992 Jul 23;327(4):269-71
pubmed: 1614468
J Perinatol. 1989 Jun;9(2):126-30
pubmed: 2738720
Turk J Pediatr. 1997 Jul-Sep;39(3):341-5
pubmed: 9339113
Cochrane Database Syst Rev. 2020 Jan 29;1:CD000361
pubmed: 31995650
J Pediatr. 1989 Dec;115(6):1013-6
pubmed: 2511290
Indian Pediatr. 1991 Apr;28(4):443-9
pubmed: 1721607
Rev Infect Dis. 1990 May-Jun;12 Suppl 4:S483-9; discussion S489-91
pubmed: 2194273
J Pediatr. 1996 Jul;129(1):63-71
pubmed: 8757564
Dev Pharmacol Ther. 1991;17(3-4):144-9
pubmed: 1841830
J Pediatr. 1989 Dec;115(6):969-71
pubmed: 2585236
Cochrane Database Syst Rev. 2004;(1):CD000361
pubmed: 14973955
Pediatr Infect Dis. 1986 May-Jun;5(3 Suppl):S171-5
pubmed: 3520501
N Engl J Med. 1992 Jul 23;327(4):213-9
pubmed: 1614462
Helv Paediatr Acta. 1989 Feb;43(4):283-94
pubmed: 2651367
Pediatr Infect Dis. 1986 May-Jun;5(3 Suppl):S198-200
pubmed: 3520507
Pediatr Infect Dis. 1986 Nov-Dec;5(6):622-5
pubmed: 3099267
Ann Surg. 1978 Jan;187(1):1-7
pubmed: 413500
Arch Dis Child Fetal Neonatal Ed. 1995 May;72(3):F151-5
pubmed: 7796228
Infection. 1990 Sep-Oct;18(5):314-24
pubmed: 2125980
Rev Infect Dis. 1990 May-Jun;12 Suppl 4:S457-61; discussion S461-2
pubmed: 2194270
J Pediatr. 1994 Dec;125(6 Pt 1):922-30
pubmed: 7996367
Arch Dis Child. 1990 Apr;65(4 Spec No):347-8
pubmed: 2186706
Pediatr Infect Dis. 1986 May-Jun;5(3 Suppl):S185-8
pubmed: 3520504
J Pediatr. 1989 Dec;115(6):973-8
pubmed: 2585237
Rev Infect Dis. 1990 May-Jun;12 Suppl 4:S443-55; discussion S455-6
pubmed: 2114035
Pediatr Infect Dis J. 1989 May;8(5):315-22
pubmed: 2471136
Clin Perinatol. 1993 Mar;20(1):211-24
pubmed: 8458166
J Clin Immunol. 1990 Nov;10(6 Suppl):40S-46S
pubmed: 2081788
Arch Dis Child Fetal Neonatal Ed. 1994 May;70(3):F182-7
pubmed: 8198411
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Semin Perinatol. 1991 Jun;15(3 Suppl 2):41-6
pubmed: 1887261